Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomas

12 Mar 2019

Abstract excerpt

The Epstein-Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available. We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EBV (EBNA1), either targeted to the DEC205 receptor on DCs or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector, improved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31042161
DOI: 10.1172/jci125364

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomasPMID 31042161Read ↗

Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responsesSemantic proximity Read ↗

Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based ImmunotherapySemantic proximity Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regressionSemantic proximity Read ↗

Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunitySemantic proximity Read ↗

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in miceSemantic proximity Read ↗

Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsSemantic proximity Read ↗

Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4<sup>+</sup>- and CD8<sup>+</sup>-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal CarcinomaSemantic proximity Read ↗

Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cellsSemantic proximity Read ↗

The Immune System – Friend or Foe for Adenovirus Based Therapies?Semantic proximity Read ↗

Human innate lymphoid cell activation by adenoviruses is modified by host defence proteins and neutralizing antibodiesSemantic proximity Read ↗

Epstein‐Barr virus nuclear antigen 1 evades direct immune recognition by CD4<sup>+</sup> T helper cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.